Optical molecular imaging and its emerging role in colorectal cancer.
Colorectal cancer remains a major cause of morbidity and mortality in the United States. The advent of molecular therapies targeted against specific, stereotyped cellular mutations that occur in this disease has ushered in new hope for treatment options. However, key questions regarding optimal dosing schedules, dosing duration, and patient selection remain unanswered. In this review, we describe how recent advances in molecular imaging, specifically optical molecular imaging with fluorescent probes, offer potential solutions to these questions. We begin with an overview of optical molecular imaging, including discussions on the various methods of design for fluorescent probes and the clinically relevant imaging systems that have been built to image them. We then focus on the relevance of optical molecular imaging to colorectal cancer. We review the most recent data on how this imaging modality has been applied to the measurement of treatment efficacy for currently available as well as developmental molecularly targeted therapies. We then conclude with a discussion on how this imaging approach has already begun to be translated clinically for human use.
Sheth
Rahul A
RA
Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Mahmood
Umar
U
D000970:Antineoplastic Agents / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D057054:Molecular Imaging / Q000295:instrumentation* / Q000379:methods*; D013194:Staining and Labeling / Q000379:methods
D000970:Antineoplastic Agents